Background: Bicuspid aortic valve (BAV) disease is considered the most common congenital heart disease and the main etiology of aortic valve stenosis (AS) in young adults. Although transcatheter aortic valve replacement (TAVR) is routinely used in high-and intermediate-risk patients with AS, BAV patients with AS were excluded from all pivotal trials that led to TAVR approval. We sought, therefore, to examine in-hospital outcomes of patients with BAV who underwent TAVR in comparison with surgical aortic valve replacement (SAVR). Methods: Using the National Inpatient Sample from 2011 to 2014, we identified patients with BAV with International Classification of Diseases-Ninth Revision-CM code 746.4. Patients who underwent TAVR were identified using ICD-9 codes 35.05 and 35.06 and those who underwent SAVR were identified using codes 35.21 and 35.22 during the same period. Results: A total of 37,052 patients were found to have BAV stenosis. Among them, 36,629 patients (98.8%) underwent SAVR, whereas 423 patients (1.14%) underwent TAVR. One-third of enrolled patients were female, and the majority of the patients were White with a mean age of 65.9 ± 15.1 years. TAVR use for BAV stenosis significantly increased from 0.39% in 2011 to 4.16% in 2014 (P < 0.001), which represents a 3.77% overall growth in procedure rate. The median length of stay decreased significantly throughout the study period (mean 12.2 ± 8.2 days to 7.1 ± 5.9 days, P < 0.001). There was no statistically significant difference between SAVR and TAVR groups in the in-hospital mortality (0% vs. 5.9%; adjusted P = 0.119). Conclusion: There is a steady increase in TAVR use for BAV stenosis patients along with a significant decrease in length of stay.
INTRODUCTION
Bicuspid aortic valve (BAV) disease is considered the most common congenital heart disease and the most common cause of aortic valve stenosis (AS) in young adults. Up to 50% of patients with BAV require aortic valve replacement in their lifetime. [1] This is because of the flow hemodynamics of the aortic valve which expedites the degeneration of the valve leaflets prematurely. The current guidelines recommend routine echocardiogram follow-up of patients with BAV to evaluate the valve hemodynamics, severity of the valve stenosis, and the left ventricular function.
Although transcatheter aortic valve replacement (TAVR) has been used routinely in high-and extreme-risk AS patients, BAV patients with AS were excluded from many pivotal trials that led to approval of TAVR in the United States. [2] [3] [4] [5] This is mainly due to the concomitant aortopathy, which requires aortic root repair with a potential increased risk of aortic dissection and numerous technical challenges related to bicuspid anatomy. [6] [7] [8] Therefore, the treatment of choice for symptomatic bicuspid stenosis has been surgical aortic valve replacement (SAVR). [9] With the advances in device technology, and with the accumulated experience, there has been an increased offlabel use of TAVR for bicuspid stenosis in the absence of aortopathy. [10] Majority of the evidence for safety and feasibility of TAVR in patients with BAV is based on registry data and single-center experiences. There are limited data regarding the use and outcome of TAVR in BAV stenosis in the United States. We sought, therefore, to assess the trend of TAVR use in patients with BAV stenosis over the past few years and examine the subsequent in-hospital and procedural outcomes.
MATERIALS AND METHODS
Data were obtained from the Agency for Healthcare and Research, and Quality Healthcare Cost and Utilization Project National Inpatient Sample (NIS) files from January 1, 2011 through December 31, 2014. The NIS is the largest, publicly available, all-payer administrative claims database in the United States. It contains de-identified patient and clinical data from approximately 1,000 nonfederal hospitals in 45 states, including approximately 5-8 million discharges annually. [11] We identified patients with BAV with International Classification of Diseases-Ninth Revision-CM (ICD-9) code 746.4. Patients undergoing TAVR were identified using ICD-9 codes 35.05 and 35.06. We also obtained the data of those who underwent SAVR were identified using ICD-9 codes 35.21 and 35.22 during the same period. To maintain a homogenous study population and to limit confounding, those with concomitant aortic valve disease were excluded from the analysis in addition to patients undergoing concomitant procedures. Procedure-related complications were identified using appropriate ICD-9-CM codes in any secondary diagnosis field. All measures for comorbidities, except coronary artery disease and anticoagulation history, were created from definitions in the Elixhauser Co-morbidity Index, which assigns variables that identify comorbidities in hospital discharge records using the diagnosis coding of ICD-9-CM. [12] Major complications were recorded using established Valve Academic Research Consortium (VARC II) definitions for death, major bleeding, myocardial infarction, stroke, vascular complications, valve-related dysfunction, and acute kidney injury. [13] Hospital length of stay (LOS) was defined as the number of days from the date of the procedure to the date of being discharged home or to a rehabilitation facility.
A value of P < 0.05 was considered statistically significant. We used the Statistical Package for the Social Sciences software version 25.0 software (IBM, Armonk, NY) for all statistical analyses.
To account for potential confounding factors and reduce the effect of selection bias, a propensity-score-matching model was developed to derive two matched groups for comparative outcomes analysis. Propensity score was calculated using multivariable logistic regression models derived from hospital level, clinical, and demographic covariates, including the Elixhauser comorbidities. For calculation of the propensity score, the dependent variable was the TAVR vs. SAVR procedure use. We performed matching on the propensity score implementing a greedy algorithm to construct a balanced match of TAVR cases to SAVR cases in a 1:1 ratio using a caliper of 0.1. As we used publicly accessible, de-identified administrative level aggregate data, rather than patient-specific data, approval from the institutional review board was not required to conduct the study.
RESULTS
A total of 37,052 patients were found to have BAV stenosis. Among them, 36,629 patients (98.8%) underwent SAVR, whereas 423 patients (1.14%) underwent TAVR between January 1, 2011, and December 31, 2014. Compared with SAVR counterparts, patients with BAV who underwent TAVR were older (65.9 years ± 15.1 vs. 56.7 years ± 14.7), had more Caucasian women (34.3% vs. 26.3%), but had more co-morbidities, particularly CAD, hyperlipidemia, prior stroke, and complicated diabetes [ Table 1 ]. The vast majority of TAVR procedures were performed in large teaching hospitals. Baseline differences existed between the groups after the propensity-adjusted analysis [ Table 2 ].
The number of patients with a BAV stenosis who underwent TAVR significantly increased from 0.39% in 2011 to 4.16% in 2014 (P < 0.001), which represents a 3.77% overall growth in procedure rate [ Figure 1 ]. The median LOS was 10.2 days and decreased significantly throughout the above period No statistically significant difference in the need for permanent pacemaker placement or the incidence postoperative aortic rupture was observed. On the contrary, the overall vascular complications, the need for blood transfusion, and the requirement for emergent open cardiac surgery have declined over the same period [ Figure 3 ].
After propensity matching of 68 patients [ Table 3 and Figure 4 ], there was no statistically significant difference between SAVR and TAVR groups in the in-hospital mortality (0% vs. 5.9%; adjusted P = 0.119), vascular and cardiac complications, perioperative stroke, acute kidney injury, and permanent pacemaker placement between the two groups. On the contrary, respiratory complications were significantly lower in patients who underwent TAVR (11.8% vs. 29.4%, adjusted P = 0.011).
DISCUSSION
The findings of our study suggest an increase in the adoption of TAVR for BAV stenosis patients in the United States with overall comparable in-hospital outcomes in those who underwent TAVR and their counterpart in the SAVR cohort.
Patients with BAV were excluded from major early TAVR trials [2] [3] [4] [5] because of several concerns that BAV anatomy might lead to a less than optimal prosthetic valve positioning and expansion leading to significant paravalvular regurgitation or annulus rupture. In addition, the presence of concomitant aortopathy with a potential increased risk of aortic dissection or rupture as well as a questionable long-term durability of transcatheter valves in younger patients with longer life expectancy. Nevertheless, the accumulated experience and advances in device technology have led to the increased off-label use of TAVR for bicuspid AS. [10] Early report by Wijesinghe et al. [14] showed the feasibility of TAVR in 11 patients with severe BAV stenosis. Edwards SAPIEN valves (Edwards Lifesciences, Irvine, CA) were implanted successfully in all patients with significant hemodynamic improvement, but two patients (18.2%) had a moderate paravalvular leak. Although Mylotte et al. [15] showed that TAVR using the first-generation balloon-expandable valves More recently, Perlman et al. [16] showed that TAVR in BAV stenosis using a new-generation device was feasible and effective with favorable valve performance and no cases of moderate or severe aortic regurgitation. Yoon et al. [17] provided a head-to-head comparison between the early-and new-generation devices in BAV stenosis patients Among patients with a BAV, 0.9% encountered problems during the TAVR procedure that required converting to open-heart surgery, compared with 0.4% of patients in the tricuspid group. [18] In terms of respiratory complications, our analysis showed a significantly fewer respiratory-related complications (including post-operative pneumothorax, pulmonary edema, pulmonary collapse, prolonged mechanical ventilation, and tracheostomy) in the TAVR group. This favorable respiratory-related outcomes in TAVR is in line with previous reports and could be explained by the shorter intubation period during TAVR procedures compared to SAVR as well as the fact that open cardiac surgery would likely cause more pain and hence increased use of analgesics that can suppress the respiratory drive thus might result in respiratory failure, atelectasis, or aspiration pneumonia. [19] Figure 3: In-hospital outcomes following TAVR in patient with BAV stenosis
Limitation
Our study has the following limitations. The analysis of the large administrative data is inherently prone to error because of potential inaccurate coding. However, the NIS database is a reliable source with broad applicability, given its large sample size. Outcome analysis was limited to in-hospital outcomes with no outcomes or complications after discharge were not recorded. Given the patients with BAV are often, younger compared with tricuspid AS, the durability of TAVR prosthesis is of interest, and this is what not captured in this database. In addition, TAVR procedures in this cohort of patients were done using old generation valves, and we were unable to delineate a change of outcome based on the prosthesis or delivery system that was used. 
CONCLUSIONS
This study shows a steadily increase in the adoption of TAVR for BAV stenosis patients in the United States along with a significant decrease in LOS. TAVR seems a safe and effective therapy in patients with BAV stenosis without aortopathy as compared with SAVR. Further research with multi-institutional studies is warranted to assess the longterm durability and complications associated with TAVR in this patient population.
Financial support and sponsorship
Nil. 
